n(g),n(g')-dimethyl-l-arginine has been researched along with Vascular Diseases in 32 studies
N,N-dimethylarginine: asymmetric dimethylarginine; do not confuse with N,N'-dimethylarginine
Vascular Diseases: Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of endothelium nitric oxide synthesis and causes endothelial dysfunction that may be related to sarcopenia." | 8.31 | Association between asymmetric dimethylarginine and sarcopenia in community-dwelling older women. ( Fukuo, K; Imamura, T; Otaki, N; Tanino, N; Yano, M; Yokoro, M, 2023) |
| "Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of endothelium nitric oxide synthesis and causes endothelial dysfunction that may be related to sarcopenia." | 4.31 | Association between asymmetric dimethylarginine and sarcopenia in community-dwelling older women. ( Fukuo, K; Imamura, T; Otaki, N; Tanino, N; Yano, M; Yokoro, M, 2023) |
| "Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, plays a role in endothelial dysfunction, an initial step of atherosclerosis." | 3.79 | Involvement of advanced glycation end product-induced asymmetric dimethylarginine generation in endothelial dysfunction. ( Ando, R; Fukami, K; Kaida, Y; Kaifu, K; Miyazaki, H; Nakayama, Y; Obara, N; Okuda, S; Takeuchi, M; Ueda, S; Yamagishi, S; Yokoro, M, 2013) |
| " The ADMA-mediated regulation of nitric oxide (NO) production is determined by the quantitative bioavailability of intracellular and extracellular ADMA." | 2.44 | Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of L-arginine on its metabolism. ( Sim, AS; Wang, J; Wang, XL; Wilcken, DE, 2007) |
| " It is released by the endothelium, and reduced NO bioavailability is responsible for impaired endothelium-dependent vasorelaxation in hyperhomocyst(e)inemia and other metabolic disorders associated with vascular disease." | 2.43 | Asymmetric dimethyl-L-arginine (ADMA): a possible link between homocyst(e)ine and endothelial dysfunction. ( Stanger, O; Stühlinger, MC, 2005) |
| "Many vascular diseases have a reduction in the activity of endothelium-derived NO as an important component involved in the initiation and/or progression of the disease." | 2.41 | Mechanisms of dysfunction of the nitric oxide pathway in vascular diseases. ( Maxwell, AJ, 2002) |
| "Dimethylarginine dimethylaminohydrolase (DDAH) 1 maintains the bioavailability of nitric oxide by degrading asymmetric dimethylarginine (ADMA)." | 1.72 | The effect of haptoglobin genotype on the association of asymmetric dimethylarginine and DDAH 1 polymorphism with diabetic macroangiopathy. ( Deng, Z; Hu, C; Jia, W; Wang, S; Yan, D; Zhang, H; Zhang, R; Zheng, X, 2022) |
| "Acute lymphoblastic leukemia (ALL) and its treatment are associated with endothelial dysfunction (ED) and increased cardiovascular risk in adulthood." | 1.48 | Plethysmographic and biochemical markers in the diagnosis of endothelial dysfunction in pediatric acute lymphoblastic leukemia survivors - new applications. ( Huml, M; Jehlička, P; Kreslová, M; Masopustová, A; Sýkora, J; Trefil, L; Votava, T, 2018) |
| "Subclinical hypothyroidism is associated with increased levels of serum endocan, ADMA, and TGF-β, which are new markers for ED." | 1.43 | Endocan, TGF-beta, and ADMA as Risk Factors for Endothelial Dysfunction and Possible Vascular Disease in Patients with Subclinical Hypothyroidism. ( Arpaci, D; Ciftci, IH; Ergenc, H; Gurol, G; Karakece, E; Tamer, A; Tocoglu, AG, 2016) |
| "Our data suggested that NAFLD is associated with endothelial dysfunction and increased earlier in patients with atherosclerosis compared to control subjects." | 1.39 | Assessment of endothelial function in patients with nonalcoholic fatty liver disease. ( Colak, Y; Coskunpinar, E; Doganay, L; Kahraman, OT; Mesci, B; Ozturk, O; Senates, E; Tuncer, I; Ulasoglu, C; Yesil, A; Yilmaz, Y, 2013) |
| " Reduced bioavailability of nitric oxide (NO) is a principal manifestation of underlying endothelial dysfunction, which is an initial event in vascular disease." | 1.38 | Cellular hypomethylation is associated with impaired nitric oxide production by cultured human endothelial cells. ( Barroso, M; Blom, HJ; Castro, R; de Almeida, IT; Esse, R; Gomes, AQ; Gonçalves, I; Jakobs, C; Loscalzo, J; Rivera, I; Rocha, MS; Teerlink, T, 2012) |
| "Treatment with sirolimus, as compared with MMF, was associated with significantly lower ADMA levels (0." | 1.35 | Asymmetric dimethylarginine and cardiac allograft vasculopathy progression: modulation by sirolimus. ( Chin, C; Cooke, JP; Fearon, WF; Holweg, C; Lewis, DB; Luikart, H; Mocarski, ES; Potena, L; Sydow, K; Valantine, HA; Weisshaar, D, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (34.38) | 29.6817 |
| 2010's | 17 (53.13) | 24.3611 |
| 2020's | 4 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Rodionov, RN | 1 |
| Jarzebska, N | 1 |
| Burdin, D | 1 |
| Todorov, V | 1 |
| Martens-Lobenhoffer, J | 1 |
| Hofmann, A | 1 |
| Kolouschek, A | 1 |
| Cordasic, N | 1 |
| Jacobi, J | 1 |
| Rubets, E | 1 |
| Morawietz, H | 1 |
| O'Sullivan, JF | 1 |
| Markov, AG | 1 |
| Bornstein, SR | 1 |
| Hilgers, K | 1 |
| Maas, R | 1 |
| Pfluecke, C | 1 |
| Chen, Y | 1 |
| Bode-Böger, SM | 1 |
| Hugo, CPM | 1 |
| Hohenstein, B | 1 |
| Weiss, N | 1 |
| Pagkopoulou, E | 1 |
| Soulaidopoulos, S | 1 |
| Triantafyllidou, E | 1 |
| Loutradis, C | 1 |
| Malliari, A | 1 |
| Kitas, GD | 1 |
| Garyfallos, A | 1 |
| Dimitroulas, T | 1 |
| Wang, S | 3 |
| Deng, Z | 3 |
| Zhang, H | 3 |
| Zhang, R | 3 |
| Yan, D | 3 |
| Zheng, X | 3 |
| Jia, W | 3 |
| Hu, C | 3 |
| Yokoro, M | 2 |
| Otaki, N | 1 |
| Yano, M | 1 |
| Imamura, T | 1 |
| Tanino, N | 1 |
| Fukuo, K | 1 |
| Masopustová, A | 1 |
| Jehlička, P | 1 |
| Huml, M | 1 |
| Votava, T | 1 |
| Trefil, L | 1 |
| Kreslová, M | 1 |
| Sýkora, J | 1 |
| Jud, P | 1 |
| Hafner, F | 1 |
| Verheyen, N | 1 |
| Meinitzer, A | 1 |
| Gary, T | 1 |
| Brodmann, M | 1 |
| Seinost, G | 1 |
| Hackl, G | 1 |
| Ando, R | 1 |
| Ueda, S | 1 |
| Yamagishi, S | 1 |
| Miyazaki, H | 1 |
| Kaida, Y | 1 |
| Kaifu, K | 1 |
| Nakayama, Y | 1 |
| Obara, N | 1 |
| Fukami, K | 1 |
| Takeuchi, M | 1 |
| Okuda, S | 1 |
| Ballard, KD | 1 |
| Mah, E | 1 |
| Guo, Y | 1 |
| Pei, R | 1 |
| Volek, JS | 1 |
| Bruno, RS | 1 |
| Vasilev, V | 1 |
| Matrozova, J | 1 |
| Elenkova, A | 1 |
| Vandeva, S | 1 |
| Kirilov, G | 1 |
| Zacharieva, S | 1 |
| Yilmaz, MI | 1 |
| Sonmez, A | 1 |
| Saglam, M | 1 |
| Yaman, H | 1 |
| Unal, HU | 1 |
| Gok, M | 1 |
| Cetinkaya, H | 1 |
| Eyileten, T | 1 |
| Oguz, Y | 1 |
| Sari, S | 1 |
| Yildirim, AO | 1 |
| Vural, A | 1 |
| Carrero, JJ | 1 |
| Blanco-Colio, LM | 1 |
| Trøseid, M | 1 |
| Nestvold, TK | 1 |
| Nielsen, EW | 1 |
| Thoresen, H | 1 |
| Seljeflot, I | 1 |
| Lappegård, KT | 1 |
| Lukkhananan, P | 1 |
| Thawonrachat, N | 1 |
| Srihirun, S | 1 |
| Swaddiwudhipong, W | 1 |
| Chaturapanich, G | 1 |
| Vivithanaporn, P | 1 |
| Unchern, S | 1 |
| Visoottiviseth, P | 1 |
| Sibmooh, N | 1 |
| Arpaci, D | 1 |
| Karakece, E | 1 |
| Tocoglu, AG | 1 |
| Ergenc, H | 1 |
| Gurol, G | 1 |
| Ciftci, IH | 1 |
| Tamer, A | 1 |
| Schepers, E | 1 |
| Glorieux, G | 1 |
| Dhondt, A | 1 |
| Leybaert, L | 1 |
| Vanholder, R | 1 |
| Soro-Paavonen, A | 1 |
| Zhang, WZ | 1 |
| Venardos, K | 1 |
| Coughlan, MT | 1 |
| Harris, E | 1 |
| Tong, DC | 1 |
| Brasacchio, D | 1 |
| Paavonen, K | 1 |
| Chin-Dusting, J | 1 |
| Cooper, ME | 1 |
| Kaye, D | 1 |
| Thomas, MC | 1 |
| Forbes, JM | 1 |
| Förstermann, U | 1 |
| Marín, M | 1 |
| Máñez, S | 1 |
| Bassareo, PP | 1 |
| Puddu, M | 1 |
| Flore, G | 1 |
| Deidda, M | 1 |
| Manconi, E | 1 |
| Melis, A | 1 |
| Fanos, V | 1 |
| Mercuro, G | 1 |
| Barroso, M | 1 |
| Rocha, MS | 1 |
| Esse, R | 1 |
| Gonçalves, I | 1 |
| Gomes, AQ | 1 |
| Teerlink, T | 1 |
| Jakobs, C | 1 |
| Blom, HJ | 1 |
| Loscalzo, J | 1 |
| Rivera, I | 1 |
| de Almeida, IT | 1 |
| Castro, R | 1 |
| Frieling, H | 1 |
| Leitmeier, V | 1 |
| Haschemi-Nassab, M | 1 |
| Kornhuber, J | 1 |
| Rhein, M | 1 |
| Bleich, S | 1 |
| Hillemacher, T | 1 |
| Colak, Y | 1 |
| Senates, E | 1 |
| Yesil, A | 1 |
| Yilmaz, Y | 1 |
| Ozturk, O | 1 |
| Doganay, L | 1 |
| Coskunpinar, E | 1 |
| Kahraman, OT | 1 |
| Mesci, B | 1 |
| Ulasoglu, C | 1 |
| Tuncer, I | 1 |
| Asif, M | 1 |
| Soiza, RL | 1 |
| McEvoy, M | 1 |
| Mangoni, AA | 1 |
| McCarty, MF | 1 |
| Stühlinger, MC | 1 |
| Stanger, O | 1 |
| Sela, BA | 1 |
| Jiang, DJ | 1 |
| Jia, SJ | 1 |
| Yan, J | 1 |
| Zhou, Z | 1 |
| Yuan, Q | 1 |
| Li, YJ | 1 |
| Zheng, YN | 1 |
| Wang, YQ | 1 |
| Konishi, H | 1 |
| Sydow, K | 2 |
| Cooke, JP | 2 |
| Wilcken, DE | 1 |
| Sim, AS | 1 |
| Wang, J | 1 |
| Wang, XL | 1 |
| Desai, A | 1 |
| Zhao, Y | 1 |
| Warren, JS | 1 |
| Potena, L | 1 |
| Fearon, WF | 1 |
| Holweg, C | 1 |
| Luikart, H | 1 |
| Chin, C | 1 |
| Weisshaar, D | 1 |
| Mocarski, ES | 1 |
| Lewis, DB | 1 |
| Valantine, HA | 1 |
| Maxwell, AJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Regulation of Postprandial Nitric Oxide Bioavailability and Vascular Function By Dairy Fat[NCT02482610] | 22 participants (Actual) | Interventional | 2016-06-30 | Completed | |||
| Regulation of Postprandial Nitric Oxide Bioavailability and Vascular Function By Dairy Milk[NCT02482675] | 23 participants (Actual) | Interventional | 2015-06-30 | Completed | |||
| Vasoprotective Activities of Low-Fat Milk in Individuals With Metabolic Syndrome[NCT01411293] | 21 participants (Actual) | Interventional | 2011-08-31 | Completed | |||
| Effect of Oral Supplementation With One Form of L-arginine on Vascular Endothelial Function in Healthy Subjects Featuring Risk Factors Related to the Metabolic Syndrome.[NCT02354794] | 36 participants (Actual) | Interventional | 2014-02-28 | Completed | |||
| Characterization of the Metabolic Fate of an Oral L-arginine Form in Healthy Subjects Featuring Risk Factors Related to the Metabolic Syndrome.[NCT02352740] | 32 participants (Actual) | Interventional | 2013-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Biomarker of nitric oxide homeostasis is based on the assessment of total nitrite and nitrate concentrations. Changes relative to baseline were used to calculate area under the curve of total nitric oxide metabolites from 0-180 min, i.e. Area Under the Curve (AUC) of change from baseline in nitric oxide homeostasis from 0 min to 180 min (i.e., AUC (NOx 0 min- 0 min, NOx 30 min-0 min, NOx 60 min-0 min, etc) (NCT02482610)
Timeframe: Area under curve of nitrite/nitrate for three hours (0, 30, 60, 90, 120, 150, and 180 min)
| Intervention | umol/L*min (Mean) |
|---|---|
| Glucose | -2229 |
| Glucose With Whole Fat Milk | -1240 |
| Glucose With Non-fat Milk | -1221 |
Glucose concentrations evaluated on the basis as change from baseline to calculate glucose area under the curve from 0-180 min, i.e. Area Under the Curve (AUC) of change from baseline in glucose from 0 min to 180 min (i.e., AUC (glucose 0 min- 0 min, glucose 30 min-0 min, glucose 60 min-0 min, etc) (NCT02482610)
Timeframe: Area under curve of glucose for three hours (0, 30, 60, 90, 120, 150, and 180 min)
| Intervention | mg/dL*min (Mean) |
|---|---|
| Glucose | 6259 |
| Glucose With Whole Fat Milk | 4481 |
| Glucose With Non-fat Milk | 3408 |
MDA concentrations evaluated on the basis as change from baseline to calculate MDAarea under the curve from 0-180 min, i.e. Area Under the Curve (AUC) of change from baseline in MDA from 0 min to 180 min (i.e., AUC (MDA 0 min- 0 min, MDA 30 min-0 min, MDA 60 min-0 min, etc) (NCT02482610)
Timeframe: Area under curve of MDA for three hours (0, 30, 60, 90, 120, 150, 180 min)
| Intervention | umol/L*min (Mean) |
|---|---|
| Glucose | 54.9 |
| Glucose With Whole Fat Milk | 25.78 |
| Glucose With Non-fat Milk | 31.3 |
Flow mediated dilation (FMD) evaluated on the basis as change from baseline to calculate FMD area under the curve from 0-180 min, i.e. i.e. Area Under the Curve (AUC) of change from baseline in FMD from 0 min to 180 min (i.e., AUC (FMD 0 min- 0 min, FMD 30 min-0 min, FMD 60 min-0 min, etc) (NCT02482610)
Timeframe: Area under curve of FMD for three hours (0, 30, 60, 90, 120, 150, and 180 min)
| Intervention | %*min (Mean) |
|---|---|
| Glucose | -195.9 |
| Glucose With Whole Fat Milk | -6.181 |
| Glucose With Non-fat Milk | -5.629 |
Plasma 8-isoprostaglandin-F2a concentration, calculated as 8-isoprostaglandin-F2a AUC from 0-180 minutes (NCT02482675)
Timeframe: 8-isoprostaglandin-F2a area under the curve for 3 hours (0, 30, 60, 90, 120, 150, 180 minutes) (change from baseline)
| Intervention | pg/mL*min (Mean) |
|---|---|
| Glucose | 2162.2 |
| Glucose With Non-fat Milk | -824.14 |
| Glucose With Whey Protein Isolate | -18.75 |
| Glucose With Sodium Caseinate | 229.14 |
Plasma 8-isoprostaglandin-F2a/Arachidonic acid concentration, calculated as 8-isoprostaglandin-F2a/Arachidonic acid AUC from 0-180 minutes (NCT02482675)
Timeframe: 8-isoprostaglandin-F2a/Arachidonic acid area under the curve for 3 hours (0, 30, 60, 90, 120, 150, 180 minutes) (change from baseline)
| Intervention | (pg/mL)/(ug/mL)*min (Mean) |
|---|---|
| Glucose | 10129 |
| Glucose With Non-fat Milk | -1655.2 |
| Glucose With Whey Protein Isolate | 2422.3 |
| Glucose With Sodium Caseinate | 3907.6 |
Arachidonic acid concentration, calculated as Arachidonic acid AUC from 0-180 minutes (NCT02482675)
Timeframe: Arachidonic acid area under the curve for 3 hours (0, 30, 60, 90, 120, 150, 180 minutes) (change from baseline)
| Intervention | ug/mL*min (Mean) |
|---|---|
| Glucose | -2570 |
| Glucose With Non-fat Milk | -1358.4 |
| Glucose With Whey Protein Isolate | -2762.6 |
| Glucose With Sodium Caseinate | -2752.0 |
Plasma arginine concentration, calculated as ARG AUC from 0-180 minutes (NCT02482675)
Timeframe: ARG area under the curve for 3 hours (0, 30, 60, 90, 120, 150, 180 minutes) (change from baseline)
| Intervention | umol/L*min (Mean) |
|---|---|
| Glucose | -3922 |
| Glucose With Non-fat Milk | -1235 |
| Glucose With Whey Protein Isolate | 195 |
| Glucose With Sodium Caseinate | -189 |
Plasma ADMA/arginine concentration, calculated as ADMA/ARG AUC from 0-180 minutes (NCT02482675)
Timeframe: ADMA/ARG area under the curve for 3 hours (0, 30, 60, 90, 120, 150, 180 minutes) (change from baseline)
| Intervention | (nmol/L)/(umol/L)*min (Mean) |
|---|---|
| Glucose | 275 |
| Glucose With Non-fat Milk | 55 |
| Glucose With Whey Protein Isolate | 47 |
| Glucose With Sodium Caseinate | 25 |
Plasma CCK concentration, calculated as CCK AUC from 0-180 minutes (NCT02482675)
Timeframe: CCK area under the curve for 3 hours (0, 30, 60, 90, 120, 150, 180 minutes) (change from baseline)
| Intervention | pmol/L*min (Mean) |
|---|---|
| Glucose | 89.67 |
| Glucose With Non-fat Milk | 422.87 |
| Glucose With Whey Protein Isolate | 352.5 |
| Glucose With Sodium Caseinate | 519.94 |
Plasma insulin concentration, calculated as insulin AUC from 0-180 minutes (NCT02482675)
Timeframe: Insulin area under the curve for 3 hours (0, 30, 60, 90, 120, 150, 180 minutes) (change from baseline)
| Intervention | uIU/mL*min (Mean) |
|---|---|
| Glucose | 8179.7 |
| Glucose With Non-fat Milk | 8196.1 |
| Glucose With Whey Protein Isolate | 8654.6 |
| Glucose With Sodium Caseinate | 8656.9 |
Plasma MDA measured as MDA AUC from 0-180 minutes (NCT02482675)
Timeframe: Area under curve for MDA for three hours (0, 30, 60, 90, 120, 150, 180 min.) (change from baseline)
| Intervention | umol/L*min (Mean) |
|---|---|
| Glucose | 66.5 |
| Glucose With Non-fat Milk | 43.2 |
| Glucose With Whey Protein Isolate | 46.4 |
| Glucose With Sodium Caseinate | 45.1 |
NOx AUC for 0-180 minutes (NCT02482675)
Timeframe: Area under curve for nitrite/nitrate for three hours (0, 30, 60, 90, 120, 180 min) (change from baseline)
| Intervention | umol/L*min (Mean) |
|---|---|
| Glucose | -1363 |
| Glucose With Non-fat Milk | 347 |
| Glucose With Whey Protein Isolate | -21 |
| Glucose With Sodium Caseinate | -57.2 |
Plasma glucose concentration from 0-180 minutes (NCT02482675)
Timeframe: Area under the curve for glucose for three hours (0, 30, 60, 90, 120, 180 minutes) (change from baseline)
| Intervention | mg/dL*min (Mean) |
|---|---|
| Glucose | 5828 |
| Glucose With Non-fat Milk | 4032 |
| Glucose With Whey Protein Isolate | 3340 |
| Glucose With Sodium Caseinate | 3640 |
Plasma SDMA/arginine concentration, calculated as SDMA/ARG AUC from 0-180 minutes (NCT02482675)
Timeframe: SDMA/ARG area under the curve for 3 hours (0, 30, 60, 90, 120, 150, 180 minutes) (change from baseline)
| Intervention | (nmol/L)/(umol/L)*min (Mean) |
|---|---|
| Glucose | 175 |
| Glucose With Non-fat Milk | 31 |
| Glucose With Whey Protein Isolate | 4 |
| Glucose With Sodium Caseinate | -17 |
Plasma BH4/BH2 concentration, calculated as BH4/BH2 AUC from 0-180 minutes (NCT02482675)
Timeframe: Plasma BH4/BH2 concentration area under the curve for 3 hours (0, 30, 60, 90, 120, 150, 180 minutes) (change from baseline)
| Intervention | ratio*min (Mean) |
|---|---|
| Glucose | -47 |
| Glucose With Non-fat Milk | 78 |
| Glucose With Whey Protein Isolate | 171 |
| Glucose With Sodium Caseinate | 131 |
Flow mediated dilation (FMD) of the brachial artery, calculated as FMD AUC for 0-180 minutes (change from baseline) (NCT02482675)
Timeframe: Area under curve for FMD for three hours (0, 30, 60, 90, 120, 180 minutes)
| Intervention | %*min (Mean) |
|---|---|
| Glucose | -307 |
| Glucose With Non-fat Milk | -34.8 |
| Glucose With Whey Protein Isolate | -36.8 |
| Glucose With Sodium Caseinate | -110 |
6 reviews available for n(g),n(g')-dimethyl-l-arginine and Vascular Diseases
| Article | Year |
|---|---|
Nitric oxide and oxidative stress in vascular disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antioxid | 2010 |
Pharmacological interventions on asymmetric dimethylarginine, a clinical marker of vascular disease.
Topics: Adrenergic Antagonists; Angiotensins; Arginine; Diabetes Complications; Humans; Hydroxymethylglutary | 2011 |
Asymmetric dimethylarginine: a possible link between vascular disease and dementia.
Topics: Arginine; Brain; Dementia; Endothelium; Enzyme Inhibitors; Humans; Neuroprotective Agents; Nitric Ox | 2013 |
Asymmetric dimethyl-L-arginine (ADMA): a possible link between homocyst(e)ine and endothelial dysfunction.
Topics: Animals; Arginine; Arteriosclerosis; Endothelium, Vascular; Homocysteine; Humans; Hyperhomocysteinem | 2005 |
Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of L-arginine on its metabolism.
Topics: Arginine; Citrulline; Dietary Supplements; Hepatocytes; Homocysteine; Humans; Kidney Diseases; Liver | 2007 |
Mechanisms of dysfunction of the nitric oxide pathway in vascular diseases.
Topics: Animals; Arginine; Endothelium, Vascular; Humans; Kinetics; Nitric Oxide; Nitric Oxide Synthase; Pol | 2002 |
Mechanisms of dysfunction of the nitric oxide pathway in vascular diseases.
Topics: Animals; Arginine; Endothelium, Vascular; Humans; Kinetics; Nitric Oxide; Nitric Oxide Synthase; Pol | 2002 |
Mechanisms of dysfunction of the nitric oxide pathway in vascular diseases.
Topics: Animals; Arginine; Endothelium, Vascular; Humans; Kinetics; Nitric Oxide; Nitric Oxide Synthase; Pol | 2002 |
Mechanisms of dysfunction of the nitric oxide pathway in vascular diseases.
Topics: Animals; Arginine; Endothelium, Vascular; Humans; Kinetics; Nitric Oxide; Nitric Oxide Synthase; Pol | 2002 |
1 trial available for n(g),n(g')-dimethyl-l-arginine and Vascular Diseases
| Article | Year |
|---|---|
Low-fat milk ingestion prevents postprandial hyperglycemia-mediated impairments in vascular endothelial function in obese individuals with metabolic syndrome.
Topics: Adult; Animals; Area Under Curve; Arginine; Blood Glucose; Brachial Artery; Cross-Over Studies; Diet | 2013 |
Low-fat milk ingestion prevents postprandial hyperglycemia-mediated impairments in vascular endothelial function in obese individuals with metabolic syndrome.
Topics: Adult; Animals; Area Under Curve; Arginine; Blood Glucose; Brachial Artery; Cross-Over Studies; Diet | 2013 |
Low-fat milk ingestion prevents postprandial hyperglycemia-mediated impairments in vascular endothelial function in obese individuals with metabolic syndrome.
Topics: Adult; Animals; Area Under Curve; Arginine; Blood Glucose; Brachial Artery; Cross-Over Studies; Diet | 2013 |
Low-fat milk ingestion prevents postprandial hyperglycemia-mediated impairments in vascular endothelial function in obese individuals with metabolic syndrome.
Topics: Adult; Animals; Area Under Curve; Arginine; Blood Glucose; Brachial Artery; Cross-Over Studies; Diet | 2013 |
Low-fat milk ingestion prevents postprandial hyperglycemia-mediated impairments in vascular endothelial function in obese individuals with metabolic syndrome.
Topics: Adult; Animals; Area Under Curve; Arginine; Blood Glucose; Brachial Artery; Cross-Over Studies; Diet | 2013 |
Low-fat milk ingestion prevents postprandial hyperglycemia-mediated impairments in vascular endothelial function in obese individuals with metabolic syndrome.
Topics: Adult; Animals; Area Under Curve; Arginine; Blood Glucose; Brachial Artery; Cross-Over Studies; Diet | 2013 |
Low-fat milk ingestion prevents postprandial hyperglycemia-mediated impairments in vascular endothelial function in obese individuals with metabolic syndrome.
Topics: Adult; Animals; Area Under Curve; Arginine; Blood Glucose; Brachial Artery; Cross-Over Studies; Diet | 2013 |
Low-fat milk ingestion prevents postprandial hyperglycemia-mediated impairments in vascular endothelial function in obese individuals with metabolic syndrome.
Topics: Adult; Animals; Area Under Curve; Arginine; Blood Glucose; Brachial Artery; Cross-Over Studies; Diet | 2013 |
Low-fat milk ingestion prevents postprandial hyperglycemia-mediated impairments in vascular endothelial function in obese individuals with metabolic syndrome.
Topics: Adult; Animals; Area Under Curve; Arginine; Blood Glucose; Brachial Artery; Cross-Over Studies; Diet | 2013 |
25 other studies available for n(g),n(g')-dimethyl-l-arginine and Vascular Diseases
| Article | Year |
|---|---|
Overexpression of alanine-glyoxylate aminotransferase 2 protects from asymmetric dimethylarginine-induced endothelial dysfunction and aortic remodeling.
Topics: Amidohydrolases; Animals; Aorta; Arginine; Blood Pressure; Mice; Transaminases; Vascular Diseases | 2022 |
Asymmetric dimethylarginine correlates with worsening peripheral microangiopathy in systemic sclerosis.
Topics: Adult; Aged; Capillaries; Cross-Sectional Studies; Female; Humans; Male; Microcirculation; Microscop | 2023 |
The effect of haptoglobin genotype on the association of asymmetric dimethylarginine and DDAH 1 polymorphism with diabetic macroangiopathy.
Topics: Amidohydrolases; Diabetes Complications; Diabetes Mellitus, Type 2; Genotype; Haptoglobins; Humans; | 2022 |
The effect of haptoglobin genotype on the association of asymmetric dimethylarginine and DDAH 1 polymorphism with diabetic macroangiopathy.
Topics: Amidohydrolases; Diabetes Complications; Diabetes Mellitus, Type 2; Genotype; Haptoglobins; Humans; | 2022 |
The effect of haptoglobin genotype on the association of asymmetric dimethylarginine and DDAH 1 polymorphism with diabetic macroangiopathy.
Topics: Amidohydrolases; Diabetes Complications; Diabetes Mellitus, Type 2; Genotype; Haptoglobins; Humans; | 2022 |
The effect of haptoglobin genotype on the association of asymmetric dimethylarginine and DDAH 1 polymorphism with diabetic macroangiopathy.
Topics: Amidohydrolases; Diabetes Complications; Diabetes Mellitus, Type 2; Genotype; Haptoglobins; Humans; | 2022 |
Association between asymmetric dimethylarginine and sarcopenia in community-dwelling older women.
Topics: Aged; Arginine; Female; Humans; Independent Living; Sarcopenia; Vascular Diseases | 2023 |
Plethysmographic and biochemical markers in the diagnosis of endothelial dysfunction in pediatric acute lymphoblastic leukemia survivors - new applications.
Topics: Adolescent; Arginine; Biomarkers; C-Reactive Protein; Child; E-Selectin; Endothelium, Vascular; Fema | 2018 |
Homoarginine/ADMA ratio and homoarginine/SDMA ratio as independent predictors of cardiovascular mortality and cardiovascular events in lower extremity arterial disease.
Topics: Aged; Arginine; Biomarkers; Cardiovascular Diseases; Cardiovascular System; Female; Homoarginine; Hu | 2018 |
Involvement of advanced glycation end product-induced asymmetric dimethylarginine generation in endothelial dysfunction.
Topics: Aged; Amidohydrolases; Arginine; Atherosclerosis; Cells, Cultured; Diabetic Nephropathies; Endotheli | 2013 |
Asymmetric dimethylarginine (ADMA) and soluble vascular cell adhesion molecule 1(sVCAM-1) as circulating markers for endothelial dysfunction in patients with pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Arginine; Biomarkers; Blood Glucose; Blood Pressure; Catechola | 2013 |
Soluble TWEAK plasma levels increase after renal transplantation and associate with the improvement of endothelial function.
Topics: Adult; Arginine; Biomarkers; Brachial Artery; C-Reactive Protein; Cytokine TWEAK; Endothelium, Vascu | 2013 |
Soluble CD14 is associated with markers of vascular dysfunction in bariatric surgery patients.
Topics: Adipose Tissue; Adult; Age Factors; Arginine; Bariatric Surgery; Biomarkers; Female; Humans; Lipopol | 2015 |
Endothelial dysfunction in subjects with chronic cadmium exposure.
Topics: Arginine; Biomarkers; Cadmium Compounds; Endothelium, Vascular; Environmental Exposure; Female; Glut | 2015 |
Endocan, TGF-beta, and ADMA as Risk Factors for Endothelial Dysfunction and Possible Vascular Disease in Patients with Subclinical Hypothyroidism.
Topics: Adult; Arginine; Biomarkers; Demography; Endothelium, Vascular; Female; Humans; Hypothyroidism; Infl | 2016 |
Role of symmetric dimethylarginine in vascular damage by increasing ROS via store-operated calcium influx in monocytes.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Arginine; Calcium; Calcium Channel Blocker | 2009 |
Advanced glycation end-products induce vascular dysfunction via resistance to nitric oxide and suppression of endothelial nitric oxide synthase.
Topics: Animals; Aorta, Thoracic; Arginine; Cattle; Cells, Cultured; Diabetes Mellitus; Diabetes Mellitus, E | 2010 |
Could ADMA levels in young adults born preterm predict an early endothelial dysfunction?
Topics: Adolescent; Adult; Arginine; Early Diagnosis; Endothelium, Vascular; Female; Gestational Age; Humans | 2012 |
Cellular hypomethylation is associated with impaired nitric oxide production by cultured human endothelial cells.
Topics: Arginine; Cells, Cultured; Endothelial Cells; Gene Expression Regulation; Human Umbilical Vein Endot | 2012 |
Reduced plasma levels of asymmetric di-methylarginine (ADMA) in patients with alcohol dependence normalize during withdrawal.
Topics: Adult; Alcoholism; Arginine; Diagnostic and Statistical Manual of Mental Disorders; Germany; Homocys | 2012 |
Assessment of endothelial function in patients with nonalcoholic fatty liver disease.
Topics: Adult; Arginine; Atherosclerosis; Brachial Artery; Carotid Arteries; Carotid Intima-Media Thickness; | 2013 |
Vascular endothelium is the organ chiefly responsible for the catabolism of plasma asymmetric dimethylarginine--an explanation for the elevation of plasma ADMA in disorders characterized by endothelial dysfunction.
Topics: Amidohydrolases; Arginine; Biomarkers; Catalysis; Clinical Trials as Topic; Endothelium, Vascular; E | 2004 |
[ADMA (asymmetric dimethylarginine)--the inhibitor of nitric oxide (NO) synthesis: a new marker for vascular pathology].
Topics: Arginine; Biomarkers; Humans; Nitric Oxide; Nitric Oxide Synthase; Vascular Diseases; Vasoconstricti | 2005 |
Involvement of DDAH/ADMA/NOS pathway in nicotine-induced endothelial dysfunction.
Topics: Amidohydrolases; Animals; Arginine; Calcium; Endothelium, Vascular; Humans; Male; Nicotine; Nitric O | 2006 |
[Dimethylarginine dimethylaminohydrolase and endothelium dysfunction].
Topics: Amidohydrolases; Animals; Arginine; Endothelium, Vascular; Humans; Vascular Diseases | 2006 |
Dimethylarginine dimethylaminohydrolase promotes endothelial repair after vascular injury.
Topics: Amidohydrolases; Animals; Arginine; Cell Proliferation; Disease Models, Animal; Endothelium, Vascula | 2007 |
Human recombinant erythropoietin augments serum asymmetric dimethylarginine concentrations but does not compromise nitric oxide generation in mice.
Topics: Amidohydrolases; Animals; Arginine; Base Sequence; Cells, Cultured; DNA Primers; Endothelial Cells; | 2008 |
Asymmetric dimethylarginine and cardiac allograft vasculopathy progression: modulation by sirolimus.
Topics: Adult; Aged; Arginine; Biomarkers; Heart Transplantation; Humans; Hyperplasia; Immunosuppressive Age | 2008 |